 |
- goat polyclonal IgG, 200 µg/ml
- epitope mapping near the N-terminus of SLU7 of human origin
- recommended for detection of SLU7 of mouse, rat and human origin by WB, IP, IF and ELISA; also reactive with additional species, including canine, bovine, porcine and avian
- blocking peptide, sc-10829 P
- TransCruz reagent for Gel Supershift and ChIP applications, sc-10829 X, 200 µg/0.1 ml
|
|
| |
Ordering Information
Recommended Support Products:
(click button of application of choice)
SLU7 Background Information
In order to produce correctly spliced messenger RNA, two catalytic splicing steps are required (1-3). After catalytic step I, a major remodeling of the spliceosome occurs to establish the active site for step II (4). During the second step of mRNA splicing, exon 1 attacks an adenine-guanine (AG) dinucleotide at the 3’ splice
site (1). SLU7, the human homolog of the yeast step II splice factor Slu7, is required for selection of the correct AG (1,4,5). Human SLU7 associates with the spliceosome late in the splicing pathway prior to recognition of the 3’ splice site for step II (4). SLU7 depletion in HeLa nuclear extract reveals that SLU7 is required to hold exon 1 tightly within the spliceosome for attack on a prespecified AG (1,4). |
|
|
SLU7 (L-16)
Click on image to enlarge
|
SLU7 (L-16): sc-10829. Western blot analysis of SLU7 expression in human SLU7 transfected: sc-111150 (A) and non-transfected: sc-110760 (B) 293 whole cell lysates. SLU7 (L-16): sc-10829. Western blot analysis of SLU7 expression in non-transfected: sc-110760 (A) and human SLU7 transfected: sc-111150 (B) 293 whole cell lysates. SLU7 (L-16): sc-10829. Western blot analysis of SLU7 expression in non-transfected: sc-110760 (A) and human SLU7 transfected: sc-111150 (B) 293 whole cell lysates. |
|
Download
|
|
